NCT07542041 Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
| NCT ID | NCT07542041 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ARTIDIS AG |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-04 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-04 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study aims to answer are: * Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer? * How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment? This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance. Participants will: * Undergo a standard-of-care pancreatic biopsy or surgical procedure * Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device * Continue to receive standard treatment and care, which is not influenced by the study * Have clinical data, imaging results, and treatment outcomes collected * Be followed every 3 months for up to 2 years The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to understand and willingness to sign a written informed consent form * Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy Exclusion Criteria: * Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07542041 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07542041 currently recruiting?
Yes, NCT07542041 is actively recruiting participants. Contact the research team at julia.ortega@artidis.com for enrollment information.
Where is the NCT07542041 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT07542041 clinical trial?
NCT07542041 is sponsored by ARTIDIS AG. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.